International Aids Vaccine Initiative

🇰🇪Kenya

Country: 🇰🇪Kenya

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: -

Website: http://www.iavi.org

Clinical Trials

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

Phase 1

Conditions: HIV Infections

Interventions: Biological: rAAV1-PG9DP

First Posted Date: 2013-09-09

Last Posted Date: 2018-01-11

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 21

Registration Number: NCT01937455

Locations: 🇬🇧
Southampton Centre for Biomedical Research, Southampton, United Kingdom
🇬🇧
Surrey Clinical Research Centre, Guildford, United Kingdom

Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: SeV-G(NP) (0.2mL, 2x10^7 CIU)
Biological: SeV-G(NP) (0.2mL, 2x10^8 CIU)
Biological: Ad35-GRIN (0.5mL)

First Posted Date: 2012-10-15

Last Posted Date: 2015-08-26

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 65

Registration Number: NCT01705990

Locations: 🇷🇼
Project San Francisco, Kigali, Rwanda
🇰🇪
Kenya AIDS Vaccine Initiative, Nairobi, Kenya
🇬🇧
St. Stephen's Centre, London, United Kingdom

Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: HIV-MAG (3,000mcg)
Biological: Ad35-GRIN/ENV
Biological: GENEVAX® IL-12 (100mcg)
Biological: GENEVAX® IL-12 (1000mcg)

First Posted Date: 2011-12-22

Last Posted Date: 2013-09-02

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 75

Registration Number: NCT01496989

Locations: 🇷🇼
Projet San Francisco, Kigali, Rwanda
🇰🇪
Kenya AIDS Vaccine Initiative, Kangemi, Nairobi, Kenya
🇺🇬
Uganda Virus Research Institute-IAVI, Entebbe, Uganda

A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers

Phase 2

Completed

Conditions: HIV Infections

Interventions: Biological: DNA.HIVA
Biological: MVA.HIVA

First Posted Date: 2011-06-10

Last Posted Date: 2011-06-10

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 115

Registration Number: NCT01371175

Locations: 🇬🇧
Guys and St. Thomas' Hospital, London, United Kingdom
🇰🇪
KAVI (Kenya AIDS Vaccine Initiative), Nairobi, Kenya

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Adjuvanted GSK investigational HIV vaccine formulation 1
Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
Biological: Ad35 investigational HIV vaccine
Biological: Placebo (saline)

First Posted Date: 2010-12-21

Last Posted Date: 2013-02-11

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 147

Registration Number: NCT01264445

Locations: 🇰🇪
Kenya AIDS Vaccine Initiative, Nairobi, Kenya
🇺🇬
Uganda Virus Research Institute-IAVI, Entebbe, Uganda
🇿🇲
Zambia-Emory HIV Research Project, Lusaka, Zambia

and more 1 locations

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Ad35-ENV vaccine
Biological: Ad26.ENVA.01 vaccine
Biological: Placebo Control

First Posted Date: 2010-10-06

Last Posted Date: 2012-12-17

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 218

Registration Number: NCT01215149

Locations: 🇰🇪
Kenya AIDS Vaccine Initiative, Kangemi, Kenya
🇷🇼
Projet San Francisco, Kigali, Rwanda
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 3 locations

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: FTC/TDF
Drug: Placebo

First Posted Date: 2009-09-03

Last Posted Date: 2010-08-09

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 72

Registration Number: NCT00971230

Locations: 🇰🇪
Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya
🇰🇪
Kenya Medical Research Institute, Center for Geographic Medicine Research - Coast, Kilifi, Kenya

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Phase 1

Completed

Conditions: HIV Infection

Interventions: Drug: FTC/TDF
Drug: Placebo

First Posted Date: 2009-07-02

Last Posted Date: 2011-08-25

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 72

Registration Number: NCT00931346

Locations: 🇺🇬
MRC-Entebbe, Entebbe, Uganda

Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: ADVAX
Biological: TBC-M4
Other: Placebo

First Posted Date: 2009-05-15

Last Posted Date: 2013-02-11

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 32

Registration Number: NCT00902824

Locations: 🇬🇧
St Stephen's Centre Chelsea and Westminster Hospital, London, United Kingdom

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid

Phase 2

Completed

Conditions: Human Immunodeficiency Virus Infections
HIV Infections

Interventions: Biological: tgAAC09
Other: Formulation buffer

First Posted Date: 2009-04-27

Last Posted Date: 2012-12-17

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 91

Registration Number: NCT00888446

Locations: 🇺🇬
Uganda Virus Research Institute, Entebbe, Uganda
🇿🇦
Desmond Tutu HIV Centre Cape Town, Cape Town, South Africa
🇿🇦
Medunsa, South Africa, South Africa

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy